Key result
Prostaglandin analogs reduce intraocular pressure more than timolol but increase hyperemia risk.
Why the study?
Variations in study methodology and IOP measurement in glaucoma clinical trials create methodological challenges for synthesizing treatment efficacy and safety data.
Meta-Analysis
p-value: p=<0.05
Highlights need for standardized IOP protocols in glaucoma trials; extends prior syntheses by quantifying methodological heterogeneity.
OBJECTIVES: Primary open-angle glaucoma (POAG) is a chronic condition characterised by optic neuropathy and vision loss. Elevated intraocular pressure (IOP) can damage the optic nerve and is a risk factor for glaucoma, thus treatment usually comprises topical hypotensives. This analysis aims to address methodological issues associated with the synthesis of glaucoma clinical trial data, given variations in study methodology and IOP measurement. METHODS: Meta-regression was used to estimate how IOP varies over time for patients receiving treatment. Relative treatment effects were assessed using a random-effects mixed treatment comparison (MTC) in order to preserve randomisation and avoid selection bias. To produce clinically meaningful outputs, these analyses were combined to obtain the mean on-treatment IOP and the proportion of patients achieving different IOP targets at different time points. A further MTC estimated the probability of hyperaemia events. RESULTS: The analysis showed that after 3 months' treatment, between 58 and 83% of patients will have a > or =20% reduction in IOP and 70-93% of patients will have an absolute IOP <20 mmHg. Latanoprost and bimatoprost were found to produce significantly lower on-treatment IOP compared with timolol (p < 0.05); the difference between latanoprost and bimatoprost was not significant. Travoprost produced a lower mean IOP compared with timolol (not significant). Latanoprost-timolol was found to produce significantly lower IOP than latanoprost alone or beta-blockers. The probability of hyperaemia-type events varied between treatments from 14.8 to 63.03%. Latanoprost had significantly lower odds of hyperaemia than travoprost, bimatoprost, travoprost-timolol, or bimatoprost-timolol. CONCLUSION: This analysis suggests that latanoprost and bimatoprost produce a statistically significant reduction in IOP compared with timolol, but are associated with a higher risk of hyperaemia. Out of all the prostaglandins, latanoprost may achieve a good balance between tolerability and IOP efficacy. As with all forms of meta-analysis, the results are based on the assumption that the studies and intervention groupings are sufficiently similar to be compared.
No takes yet. Share an insight, caveat, or question.
Orme et al. (2009) conducted a meta-analysis in Primary open-angle glaucoma and ocular hypertension. Prostaglandin analogues (latanoprost, bimatoprost, travoprost) vs. Timolol and other beta-blockers was evaluated on Mean on-treatment intraocular pressure (IOP) (p=<0.05). Latanoprost and bimatoprost produced significantly lower on-treatment intraocular pressure compared with timolol (P<0.05), but were associated with a higher risk of hyperaemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: